The stock price of Exact Sciences Corp. (NASDAQ: EXAS) has surged by 2.06 when compared to previous closing price of 62.07, but the company has seen a 7.77% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-24 that In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
Is It Worth Investing in Exact Sciences Corp. (NASDAQ: EXAS) Right Now?
The 36-month beta value for EXAS is also noteworthy at 1.33. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for EXAS is 181.94M, and at present, short sellers hold a 5.44% of that float. The average trading volume of EXAS on May 07, 2024 was 2.47M shares.
EXAS’s Market Performance
The stock of Exact Sciences Corp. (EXAS) has seen a 7.77% increase in the past week, with a -9.80% drop in the past month, and a 1.46% gain in the past quarter. The volatility ratio for the week is 4.75%, and the volatility levels for the past 30 days are at 4.54% for EXAS. The simple moving average for the past 20 days is -1.62% for EXAS’s stock, with a -8.40% simple moving average for the past 200 days.
Analysts’ Opinion of EXAS
Many brokerage firms have already submitted their reports for EXAS stocks, with The Benchmark Company repeating the rating for EXAS by listing it as a “Buy.” The predicted price for EXAS in the upcoming period, according to The Benchmark Company is $91 based on the research report published on January 02, 2024 of the current year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see EXAS reach a price target of $90. The rating they have provided for EXAS stocks is “Buy” according to the report published on December 14th, 2023.
Wolfe Research gave a rating of “Outperform” to EXAS, setting the target price at $95 in the report published on December 13th of the previous year.
EXAS Trading at 0.33% from the 50-Day Moving Average
After a stumble in the market that brought EXAS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.13% of loss for the given period.
Volatility was left at 4.54%, however, over the last 30 days, the volatility rate increased by 4.75%, as shares sank -11.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.12% upper at present.
During the last 5 trading sessions, EXAS rose by +7.77%, which changed the moving average for the period of 200-days by -33.27% in comparison to the 20-day moving average, which settled at $64.00. In addition, Exact Sciences Corp. saw -14.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EXAS starting from Conroy Kevin T, who sale 1,155 shares at the price of $60.15 back on May 01 ’24. After this action, Conroy Kevin T now owns 1,156,191 shares of Exact Sciences Corp., valued at $69,473 using the latest closing price.
Cunningham Everett, the Chief Commercial Officer of Exact Sciences Corp., sale 136 shares at $60.15 during a trade that took place back on May 01 ’24, which means that Cunningham Everett is holding 47,042 shares at $8,180 based on the most recent closing price.
Stock Fundamentals for EXAS
Current profitability levels for the company are sitting at:
- -0.09 for the present operating margin
- 0.74 for the gross margin
The net margin for Exact Sciences Corp. stands at -0.08. The total capital return value is set at -0.04. Equity return is now at value -6.60, with -3.00 for asset returns.
Based on Exact Sciences Corp. (EXAS), the company’s capital structure generated 0.45 points at debt to capital in total, while cash flow to debt ratio is standing at 0.06. The debt to equity ratio resting at 0.81. The interest coverage ratio of the stock is -8.39.
Currently, EBITDA for the company is -13.13 million with net debt to EBITDA at -20.93. When we switch over and look at the enterprise to sales, we see a ratio of 5.44. The receivables turnover for the company is 12.28for trailing twelve months and the total asset turnover is 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.32.
Conclusion
In summary, Exact Sciences Corp. (EXAS) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
